Varun Malik’s Post

The future of longevity biotech holds immense promise in solving aging. However, we need to bridge the funding gap to realize this potential. It's time for investors to recognize the opportunities in this field and take action. Here are the highlights of the investment landscape in longevity biotech: 🧬 The funding for solving aging remains shockingly tiny compared to the scale of the challenge. 🌍 There are over 160 startups in longevity biotech, yet they've only amassed $13 billion in total funding. This is a drop in the ocean compared to the investment in other biotech sectors. 💸 Most of this investment comes from venture capital firms, with only 20 VCs specifically focused on longevity. Major players like Apollo Health Ventures and Hevolution Foundation are leading the charge, but it's not enough. 🚀 Imagine the possibilities with more human data from clinical trials, a potential geroscience moonshot, and regenerative medicine approaches. Companies like Newlimit, founded by Coinbase's Brian Armstrong, are pioneering reprogramming techniques to combat aging but need more support. 🚨 This is an urgent call for investors who want to make a real impact rather than chase the next "low-hanging fruit." Please spread the word, and let's turn the dream of solving aging into a reality. #LongevityBiotech #InvestmentOpportunity #FutureOfHealth

Join me and Nathan Cheng for "The State of Longevity," a live crash course where we dive into the world of longevity biotech. This webinar will provide a comprehensive overview of the key players, groundbreaking startups, major investors, and cutting-edge technologies driving the quest to extend healthy human life. Whether you're a biotech enthusiast, an investor, a health and wellness professional, or simply curious about the future of human longevity, this event is for you. Learn about the innovative approaches these startups are taking and the significant investments being made to revolutionize aging. 🗓 Date: 5th of September, 2024 ⏰ Time: 7PM (GMT+4) Don’t miss this chance to learn valuable insights and connect with like-minded individuals who share passion for the future of health and longevity.

Our latest research looks at the fundraising stats by the top VC funds to date in 2024. As I've been saying for quite some time, life sciences VCs are sitting atop record amounts of dry powder, with capital on the sidelines waiting to be deployed. Despite sector headwinds, venture firms remain bullish and have raised $10.3 billion YTD, the second highest annual raise ever- and it's not slowing. Inflation has driven the cost of all areas of drug development, from R&D, tools, talent, facilities, trials, and production/manufacturing- you name it. As such, costs to run a biotech are MUCH higher now (150-200%) than pre-pandemic, and the cost of capital is higher and more selective. This has led to more "megaround"s ($100+M) and generally widened the gap between "haves and have nots". As we move past the election cycle and have more clarity on the future economic and regulation environment, I expect a lot of money to come off the sidelines, bringing founders and early stage companies the confidence to push forward and fuel our sector's inevitable growth. But tell me what you think! Please explore this research and share your thoughts- take a chance and state your opinions or observations. Read our brand new 2024 Life Sciences Real Estate Perspective and Cluster Analysis >> https://lnkd.in/gCb_mE7N #biotech #vc #jll #innovation #biocom #4labspace #labspace

F-Prime Capital is honored to once again co-host the #Science2Startup symposium, alongside others from the biotech investment community, to identify promising science and technologies with startup potential. F-Prime's Jessica Alston, Ph.D., will serve as an advisor for the event. "S2S is more than an event; It's a beacon for innovation where top scientists worldwide come together to present their ideas and interact with leading investors and executives in Boston's established biotech ecosystem," said Dr. Alston. "Our goal is to nurture our connections while supporting the translation of scientific breakthroughs to solve the greatest challenges in #healthcare and medicine." Learn more about this unique opportunity for scientists, entrepreneurs, #biotech operators, and investor to meet, collaborate and translate exciting ideas into real innovations: www.science2startup.com

Hope everyone had a wonderful and restful labor day weekend! Can't believe we're in September already! We're gearing up for an eventful month with our Women's Pitch Competition Semifinals and Finals! Meet the judges for our upcoming semifinals pitch competition on Sept 12th! https://lnkd.in/eQAz5cW9 Rahul M. Zina Manji, M.S., PharmD Vinay Nathan 𝐑𝐚𝐡𝐮𝐥 𝐌𝐞𝐡𝐭𝐚 has been deeply immersed in the Digital Assets and Web3 space since 2017, making significant investments in numerous startups. Beyond his role as an investor, he actively contributes as an advisor to Web3 companies and hedge funds. Rahul is also an angel investor in the Web2 and AI sectors, backing prominent ventures like Anthropic, OpenAI, RainAI, and Solarcore. His expertise is frequently sought after as a speaker and panelist at Crypto and Family Office conferences and events. In addition to his financial ventures, Rahul is set to begin movie production in India in Q3 2024, and he plans to launch the Crypto TenX Digital Assets Fund in Q3 2025. 𝐙𝐢𝐧𝐚 𝐌𝐚𝐧𝐣𝐢 is the Founder & Principal of Innopathwayz, LLC, a consultancy empowering companies and individuals to develop innovative healthcare strategies that improve lives. With over 20 years in regulatory affairs, she is also a Global Fellow at HITLAB, participating in the advocacy of digital health innovation. Previously, Zina was VP and Head of Regulatory Affairs at Ellume, a digital diagnostics company, and held leadership roles at GSK Consumer Healthcare (now Haleon), where she led global regulatory strategies across OTC drugs, medical devices, cosmetics, and new and emerging technologies. Driven by a passion for creating synergies, crafting innovative strategies, and mentoring others, Zina regularly contributes to HITLAB’s monthly symposia and speaks at Columbia’s digital health programs. 𝐕𝐢𝐧𝐚𝐲 𝐍𝐚𝐭𝐡𝐚𝐧 is the CEO and Co-Founder of Altizon Inc., a leading products and solutions provider in the Industrial AI space. With over 20 years of varied experience across sales, marketing, engineering and product management, his work and travels have helped him gain a deep understanding of businesses and markets across North America, India and APAC. Vinay holds multiple patents and has a keen interest in advancing entrepreneurship globally. Vinay is adjunct faculty at Drexel University and frequently speaks on Industry 4.0, Entrepreneurship and Technology. He is a Charter Member of TiE New Jersey. Please save the date for Sept 26th and join us at the pitch competition finals event at Middlesex College, Edison NJ. Register here: https://lnkd.in/emMKHgqF To learn more about the TiE NJ Women's Program, please reach out to Nivedita Candade. TiE Women Global: https://tiewomen.org/ TiE NJ Upcoming events: https://nj.tie.org/events/ TiE NJ Women's LinkedIn group: https://lnkd.in/eP5AQ2aA #Womenfounders #entrepreneurship #pitchcompetition #venturecapital

The data is very encouraging -- Massachusetts-based investors raised nearly $5.2 billion by the end of the third quarter of 2024, and they’re on target to exceed last year’s total. According to this piece in the Boston Business Journal, many #VC firms are backing companies on the front lines of developing cardiometabolic or neuroscience drugs. Others are high on innovative ‘tough tech’ companies working in climate change, human health, and advanced systems, while others are backing firms that are developing ‘transformational medicines’ that could impact large populations of patients. 2025 could be an exciting year in #lifesciences! Please note this article is behind a paywall, although non-subscribers receive a limited number of free reads per month. 

Thank you to our 2024 #Science2Startup fireside chat speaker, David R. Liu, Ph.D., and moderator, Deborah Palestrant, Ph.D., M.B.A., for kicking off this year's event. During their discussion, Liu spoke about his professional and academic journey, how he began working with #VentureCapital organizations, how he stays committed to science and patient care, and more. "Problem selection, still very very important. Trust, give anybody who wants to work with you, the opportunity to work with you, if possible. But developing a network of people you trust is really important for translation. And ultimately, for this audience, where I noticed everything was a therapeutics company, keep patient interest upfront. That's such an important guiding star and you can virtually never go wrong if you just keep patient interest upfront, it will help everything. And you also, coincidentally, build the most value if you end up keeping patient interest upfront because all of this is not just a marathon, it's an ultramarathon, so not letting the short-term eccentricities of what an investor did or didn't do, how the value of your stock, if it's publicly traded, is changing or not; don't let that bother you. In the end, if you are actually helping people, if you keep patient interest upfront, you will generate enough value that everybody will be happy that way, and more importantly, in the end, I don't think you're going to care that much about how many digits are in your bank account, which is not even associated with physical money anymore, but I think people will remember you for the impact you had on the lives of patients who maybe didn't have a treatment otherwise." Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank │ Broad Institute of MIT and Harvard #biotech #pharma #startup

Last night, we hosted the first of our Investor-Founder Mixer Series, with this one being centred around AI Drug Discovery. Around the table we had six entrepreneurs from the BioFounder Club and six investors from the BioCapital Network - all either building or investing in AI Drug Discovery companies. Cc Octopus Ventures, Redalpine, Verve Ventures, First Spark Ventures, BACKED VC, Calculus Capital, Pear Bio, iuvantium, Cambridge Medixine Ltd., PentaBind, Xenos Bio and Stem Solutions. A huge thanks to the Amazon Web Services (AWS) life science team for sponsoring this dinner. Reach out to Natalie or Alex to find out more on their purpose-built solutions for techbio 👉 https://lnkd.in/eHmFq2gq Our Investor-Founder Dinner Series is centred around facilitating meaningful connections between investors and founders, enabling them to discuss thoughts on the industry and get to know each other in a more relaxed and personal manner. We theme each dinner around a specific area within life sciences. Everyone around the table is either building or actively investing in that space and we aim for a 1:1 investor-founder ratio. If you’re an entrepreneur and want to get involved in a future dinner, sign-up to the BioFounder Club here 👉 https://lnkd.in/eSPr6JtN If you’re an investor and want to get involved in a future dinner, sign-up to the BioCapital Network here 👉 https://lnkd.in/eWSVnKB5 If you’re interested in getting unique and intimate access to a group of both investors and founders, drop me a line about our sponsorship options for these dinners! Both the BioCapital Network and BioFounder Club are initiatives of the Science Entrepreneur Club. #investor #founder #venturecapital #innovation #lifesciences #aidrugdiscovery #ai #drugdiscovery #BioFounderClub #BioCapitalNetwork

We are happy to announce Phil Newman, Founder and CEO of Longevity.Technology, as a speaker for the #RejuvenationStartupSummit 2024 Phil will speak about ‘The longevity investment landscape’. He will cover the mapping of longevity domains and categories, key areas attracting investment; the clinical stages of longevity biotechs, the funding stages of longevity biotechs, and give an outlook for longevity investing. https://lnkd.in/eqUMCJvd #longevity #rejuvenation #aging